Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM

Jumpei Teramachi, Kazuaki Miyagawa, DDS, PhD, Delgado-Calle Jesus, PhD, Jolene Windle, PhD, Noriyoshi Kurihara, DDS, PhD, G David Roodman, MD PhD

Blood (2019) 134 (Supplement_1): 4336.

https://doi.org/10.1182/blood-2019-126959

Published: 2019

Journal Articles

A Novel Ex-Vivo Model of Prolonged Osteoblast Suppression in Multiple Myeloma

Noriyoshi Kurihara, DDS, PhD, Yasuhisa Ohata, MD PhD, Gabriel M. Pagnotti, PhD, John Chirgwin, PhD, G David Roodman, MD PhD

Blood (2017) 130 (Supplement 1): 4360.

https://doi.org/10.1182/blood.V130.Suppl_1.4360.4360

Published: 2017

Journal Articles

Inhibition of p62-ZZ Domain-Mediated Signaling Overcomes Bortezomib Resistance in Multiple Myeloma Cells Independent of Their p53 Status

Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Rebecca Silberman, MD, Denise Toscani, PhD, Judith L Anderson, Nicola Giuliani, MD PhD, Xiang-Qun Xie, PhD, Noriyoshi Kurihara, DDS, PhD, G David Roodman, MD PhD

Blood (2017) 130 (Supplement 1): 4421.

https://doi.org/10.1182/blood.V130.Suppl_1.4421.4421

Published: 2017

Journal Articles

Aplidin (Plitidepsin) Regulates Viability and Function of Myeloma Cells and Bone Cells in Combination with Other Anti-MM Drugs

Jesus Delgado-Calle, PhD, Emily G Atkinson, Jessica Nelson, Noriyoshi Kurihara, DDS, PhD, Carlos Galmarini, David David Roodman, MD PhD, Teresita Bellido

Blood (2017) 130 (Supplement 1): 3065.

https://doi.org/10.1182/blood.V130.Suppl_1.3065.3065

Published: 2017

Journal Articles

Low Intensity Vibration Treatment Reduces Myeloma Cell-Induced Osteoclast Formation By Inhibiting IL-6 and GFI-1 Production By MM Cells

Gabriel M. Pagnotti, PhD, Noriyoshi Kurihara, DDS, PhD, G David Roodman, MD PhD

Blood (2017) 130 (Supplement 1): 1775.

https://doi.org/10.1182/blood.V130.Suppl_1.1775.1775

Published: 2017

Journal Articles

p62-ZZ Domain Signaling Inhibition Rescues MM-Induced Epigenetic Repression at the Runx2 promoter and Allows Osteoblast Differentiation of MM Patient Pre-Osteoblasts In Vitro

Rebecca Silbermann, MD, Juraj Adamik, PhD, Dan Zhou, Xiang-Qun Xie, MD PhD EMBA, Noriyoshi Kurihara, DDS, PhD, G. David Roodman, MD PhD, Deborah Lynn Galson, PhD

Blood (2016) 128 (22): 4410.

https://doi.org/10.1182/blood.V128.22.4410.4410

Published: 2016

Journal Articles

Myeloma Cells Induce High Level of TAF12 Expression in Bone Marrow Stromal Cells, Resulting in Increased Osteoclastogenesis and Myeloma Cell Growth in Response to 1,25(OH) 2 D 3

Yasuhisa Ohata, MD PhD, John M Chirgwin, PhD, Jolene J Windle, PhD, G. David Roodman, MD PhD, Noriyoshi Kurihara, DDS, PhD

Blood (2016) 128 (22): 4421.

https://doi.org/10.1182/blood.V128.22.4421.4421

Published: 2016

Journal Articles

p62-ZZ Domain Inhibition Prevents MM Cell-Induced Epigenetic Changes at the Runx2 and C/EBPb Promoters

Rebecca Silbermann, MD, Juraj Adamik, PhD, Dan Zhou, Xiang-Qun Xie, MD PhD EMBA, G. David Roodman, MD PhD, Noriyoshi Kurihara, DDS, PhD, Deborah Lynn Galson, PhD

Blood (2015) 126 (23): 1796.

https://doi.org/10.1182/blood.V126.23.1796.1796

Published: 2015

Journal Articles

TAF12 Enhances the Biological Reponses of Myeloma Cells to Low Concentrations of 1,25-(OH) 2 dvitamin D 3

Noriyoshi Kurihara, DDS, PhD, Yukiko Kitagawa, MDPhD, Yuji Inagaki, DDS, PhD, Jolene J. Windle, PhD, John M Chirgwin, PhD, G. David Roodman, MD PhD

Blood (2014) 124 (21): 2066.

https://doi.org/10.1182/blood.V124.21.2066.2066

Published: 2014

Journal Articles

The p62-ZZ Domain Inhibitor XRK3F2 Alters Myeloma-Induced Suppression of Osteoblast Differentiation and Is Highly Cytotoxic to Myeloma Cells in Combination with Bortezomib

Rebecca Silbermann, MD, Dan Zhou, Jumpei Teramachi, DDS, PhD, Xiang-Qun Xie, PhD, G. David Roodman, MD PhD, Noriyoshi Kurihara, DDS, PhD

Blood (2014) 124 (21): 2083.

https://doi.org/10.1182/blood.V124.21.2083.2083

Published: 2014

Journal Articles

A Novel Sequestosome-1/p62 ZZ Domain Inhibitor Induces New Bone Formation In The Presence Of Myeloma In Vivo

Rebecca Silbermann, MD, Wei Zhao, MBBS, Julie L Eiseman, PhD, Jan H Beumer, PharmD, PhD, Xiang-Qun Xie, PhD, Peng Yang, PhD, Kyaw-Zeyar Myint, PhD, Lirong Wang, PhD, Zhiwei Feng, PhD, Jolene J. Windle, PhD, G. David Roodman, MD, PhD, Noriyoshi Kurihara, DDS, PhD

Blood (2013) 122 (21): 684.

https://doi.org/10.1182/blood.V122.21.684.684

Published: 2013

Journal Articles

The Increased 1,25-(OH) 2 D 3 Sensitivity of Myeloma Cells and Marrow Stromal Cells Enhances RANKL Production and Tumor Cell Growth

Jumpei Teramachi, DDS, PhD, Noriyoshi Kurihara, DDS, PhD, John M Chirgwin, G David Roodman, MD, PhD

Blood (2012) 120 (21): 3946.

https://doi.org/10.1182/blood.V120.21.3946.3946

Published: 2012

Journal Articles

Blocking the ZZ Domain of Sequestosome 1/p62 Suppress the Enhancement of Myeloma Cell Growth and Osteoclast Formation by Marrow Stromal Cells

Jumpei Teramachi, DDS, PhD, Kyaw Ze Yar Myint, PhD, Rentian Feng, PhD, Xiangqun Xie, PhD, Jolene J. Windle, PhD, David Roodman, MD, PhD, Noriyoshi Kurihara, DDS, PhD

Blood (2011) 118 (21): 888.

https://doi.org/10.1182/blood.V118.21.888.888

Published: 2011

Journal Articles

Annexin II Interactions with the Annexin II Receptor Enhance Multiple Myeloma Cell Adhesion and Growth in the Bone Marrow Microenvironment,

Sonia D'Souza, PhD, Noriyoshi Kurihara, DDS, PhD, Yusuke Shiozawa, MD, PhD, Jeena Joseph, Russell Taichman, MD, Deborah Galson, PhD, David Roodman, MD, PhD

Blood (2011) 118 (21): 3942.

https://doi.org/10.1182/blood.V118.21.3942.3942

Published: 2011

Journal Articles

Annexin II Interactions with the Annexin II Receptor Enhance Multiple Myeloma Cell Adhesion and Growth In the Bone Marrow Microenvironment

Sonia D'Souza, PhD, Noriyoshi Kurihara, DDS, PhD, Yusuke Shiozawa, MD, PhD, Russell Taichman, MD, Deborah Galson, PhD, David Roodman

Blood (2010) 116 (21): 130.

https://doi.org/10.1182/blood.V116.21.130.130

Published: 2010

Journal Articles

The ZZ Domain of Sequestosome-1/p62 Plays An Important Role In Stromal Cell Support of Myeloma Cell Growth and Osteoclast Formation

Jumpei Teramachi, DDS, PhD, Jolene J. Windle, PhD, David Roodman, MD, PhD, Noriyoshi Kurihara, DDS, PhD

Blood (2010) 116 (21): 128.

https://doi.org/10.1182/blood.V116.21.128.128

Published: 2010

Journal Articles

p62 Signaling Is Increased in Multiple Myeloma Microenvironment.

Yuko Hiruma, Noriyoshi Kurihara, DDS, PhD, David Roodman, MD, PhD

Blood (2007) 110 (11): 669.

https://doi.org/10.1182/blood.V110.11.669.669

Published: 2007

Journal Articles

Thalidomide Derivative CC-4047 Inhibits Osteoclast Formation by down Regulation of PU.1.

Suzanne Lentzsch, MD, PhD, Gulsum Anderson, PhD, Noriyoshi Kurihara, DDS, PhD, Tadashi Honjo, DDS, PhD, Judith Anderson, Markus Y. Mapara, MD, PhD, David Stirling, PhD, David Roodman, MD, PhD

Blood (2005) 106 (11): 629.

https://doi.org/10.1182/blood.V106.11.629.629

Published: 2005

Journal Articles

Targeting p62 ZIP in Marrow Stromal Cells Is Highly Effective at Inhibiting Myeloma Cell Growth and Osteoclast Formation.

Noriyoshi Kurihara, DDS, PhD, Tadashi Honjo, DDS, PhD, Jolene J. Windle, PhD, J. Shin, PhD, G. D. Roodman, MD, PhD

Blood (2005) 106 (11): 630.

https://doi.org/10.1182/blood.V106.11.630.630

Published: 2005

NARROW

Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM

A Novel Ex-Vivo Model of Prolonged Osteoblast Suppression in Multiple Myeloma

Inhibition of p62-ZZ Domain-Mediated Signaling Overcomes Bortezomib Resistance in Multiple Myeloma Cells Independent of Their p53 Status

Aplidin (Plitidepsin) Regulates Viability and Function of Myeloma Cells and Bone Cells in Combination with Other Anti-MM Drugs

Low Intensity Vibration Treatment Reduces Myeloma Cell-Induced Osteoclast Formation By Inhibiting IL-6 and GFI-1 Production By MM Cells

p62-ZZ Domain Signaling Inhibition Rescues MM-Induced Epigenetic Repression at the Runx2 promoter and Allows Osteoblast Differentiation of MM Patient Pre-Osteoblasts In Vitro

Myeloma Cells Induce High Level of TAF12 Expression in Bone Marrow Stromal Cells, Resulting in Increased Osteoclastogenesis and Myeloma Cell Growth in Response to 1,25(OH) 2 D 3

p62-ZZ Domain Inhibition Prevents MM Cell-Induced Epigenetic Changes at the Runx2 and C/EBPb Promoters

TAF12 Enhances the Biological Reponses of Myeloma Cells to Low Concentrations of 1,25-(OH) 2 dvitamin D 3

The p62-ZZ Domain Inhibitor XRK3F2 Alters Myeloma-Induced Suppression of Osteoblast Differentiation and Is Highly Cytotoxic to Myeloma Cells in Combination with Bortezomib

A Novel Sequestosome-1/p62 ZZ Domain Inhibitor Induces New Bone Formation In The Presence Of Myeloma In Vivo

The Increased 1,25-(OH) 2 D 3 Sensitivity of Myeloma Cells and Marrow Stromal Cells Enhances RANKL Production and Tumor Cell Growth

Blocking the ZZ Domain of Sequestosome 1/p62 Suppress the Enhancement of Myeloma Cell Growth and Osteoclast Formation by Marrow Stromal Cells

Annexin II Interactions with the Annexin II Receptor Enhance Multiple Myeloma Cell Adhesion and Growth in the Bone Marrow Microenvironment,

Annexin II Interactions with the Annexin II Receptor Enhance Multiple Myeloma Cell Adhesion and Growth In the Bone Marrow Microenvironment

The ZZ Domain of Sequestosome-1/p62 Plays An Important Role In Stromal Cell Support of Myeloma Cell Growth and Osteoclast Formation

p62 Signaling Is Increased in Multiple Myeloma Microenvironment.

Thalidomide Derivative CC-4047 Inhibits Osteoclast Formation by down Regulation of PU.1.

Targeting p62 ZIP in Marrow Stromal Cells Is Highly Effective at Inhibiting Myeloma Cell Growth and Osteoclast Formation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only